Home » Newsletters » BioWorld Science

BioWorld Science

March 30, 2007

View Archived Issues

Utility of I-123 MIBG in diagnosis of neuroblastomas

AZ-001 meets two-hour pain-relief endpoint in migraine

Topline results for CRx-139 in RA

Recent patents cover new therapeutic agents for cancer

Recent University of Dundee patent describes novel wound-healing agents

New therapeutic agents for gastrointestinal disorders reported in recent patents

New experimental data on sildenafil-doxazosin combination

INO-1001 evaluated in phase II study

BAY-68-4986 reduces heart rate in chronic angina patients

BMS-695735: a novel, improved IGF-1R inhibitor reported by BMS

ABT-888, a new PARP inhibitor, shows antitumor activity in several cancer models

Azixa studied in phase II for melanoma patients with brain metastases

AL-108 cleared for clinical study in schizophrenia-related cognitive impairment

Phase II trial evaluates belinostat with bortezomib in refractory multiple myeloma

HZT-501 begins phase II program for mild to moderate pain relief

Neugranin begins phase I/IIa study for neutropenia

United Therapeutics and Mochida sign Japanese agreement for Remodulin

CytoGenix and USAMRIID collaborate on biodefense vaccines

Phase IIb kidney transplant trial of ISA-247 clears interim review

Zyvox increases risk of death in patients with Gram-negative infections

BrainCells and Lundbeck form CNS research collaboration

Collaborative compound PS-386113 begins phase I for inflammatory disease

Phase III trial evaluates Zingo in adults

FDA accepts for review PMA for Repel-CV

Merck and Lundbeck discontinue gaboxadol development

BLA submission for Cervarix

GSK files Globorix meningococcal vaccine

E.U. approval for Xeloda for advanced stomach cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...